Itraconazole Aurobindo

Itraconazole, the active ingredient in Itraconazole Aurobindo, is a triazole antifungal presented as an oral formulation for oral use. It treats a range of systemic and superficial fungal infections, including candidiasis, aspergillosis, dermatophyte infections, onychomycosis, blastomycosis and histoplasmosis, and is prescribed for patients requiring systemic antifungal therapy.

GNH USA supplies Itraconazole Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance and reliable delivery.

Itraconazole is a triazole antifungal used to treat infections caused by a variety of fungi. - Dermatophyte infections: effective in treating skin and nail infections caused by dermatophyte fungi. - Onychomycosis: helps eradicate fungal infection of the toenails and fingernails. - Systemic candidiasis: used for invasive Candida infections affecting blood and internal organs. - Aspergillosis: indicated for invasive disease caused by Aspergillus species. - Blastomycosis: treats infection by Blastomyces dermatitidis in pulmonary or disseminated forms. - Histoplasmosis: employed in management of disseminated Histoplasma capsulatum infection.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Abdominal pain or discomfort - Headache - Rash or pruritus - Elevated liver enzymes

Serious or Rare Side Effects: - Hepatotoxicity, including severe hepatitis - Severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis - Cardiac failure or reduced left‑ventricular function - Visual disturbances, including blurred vision or photopsia - Anaphylactic or severe allergic reactions

Before initiating itraconazole therapy, several precautionary measures should be considered to ensure patient safety. - Liver function monitoring: obtain baseline liver enzymes and repeat periodically during treatment. - Drug interaction review: assess concomitant medications for potential CYP3A4 interactions. - Cardiac assessment: avoid use in patients with existing heart failure or significant ventricular dysfunction. - Pregnancy and lactation: prescribe only when benefits outweigh potential risks to the fetus or infant. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Itraconazole interacts with several medicines; understanding the interaction level guides clinical management.

Major Interactions (Avoid): - Rifampin: induces CYP3A4 and markedly reduces itraconazole plasma concentrations. - Antacids containing aluminum or magnesium: decrease oral absorption of itraconazole. - Ketoconazole: combined use may increase risk of hepatotoxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): can raise itraconazole levels and risk toxicity. - Statins such as simvastatin or lovastatin: increased exposure may lead to myopathy. - Warfarin: itraconazole may potentiate anticoagulant effect, requiring INR monitoring.